Ipratropium inhalation and Moxetumomab Pasudotox-tdfk
Determining the interaction of Ipratropium inhalation and Moxetumomab Pasudotox-tdfk and the possibility of their joint administration.
No interaction was detected between the selected drugs or effects of joint drug administration are currently understudied, and it takes time and accumulated statistics to determine their interaction. A doctor should be consulted to address the issue of joint drug administration.
Generic Name: ipratropium
Brand name: Atrovent HFA, Atrovent
Synonyms: Ipratropium (Oral Inhalation)
Generic Name: moxetumomab pasudotox
Brand name: Lumoxiti
Synonyms: Moxetumomab pasudotox, Moxetumomab Pasudotox
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Ipratropium inhalation-Moxetumomab pasudotox-tdfk Intravenous
- Ipratropium inhalation-Moxifloxacin
- Ipratropium inhalation-Moxifloxacin (Systemic)
- Ipratropium inhalation-Moxifloxacin Hydrochloride
- Ipratropium inhalation-Moxifloxacin Injection
- Ipratropium inhalation-Moxifloxacin Intravenous
- Moxetumomab Pasudotox-tdfk-Ipratropium Inhalation Aerosol
- Moxetumomab Pasudotox-tdfk-Ipratropium Inhalation Solution
- Moxetumomab Pasudotox-tdfk-Ipratropium Inhalation, oral/nebulization
- Moxetumomab Pasudotox-tdfk-Ipratropium nasal
- Moxetumomab Pasudotox-tdfk-Ipratropium Nasal 0.03
- Moxetumomab Pasudotox-tdfk-Ipratropium Nasal 0.06